SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
{{output}}
Objective: CR1447, a novel transdermal formulation of 4-hydroxytestosterone, has aromatase-inhibiting and androgen receptor (AR)-modulating properties (IC504.4 nM) with antitumor effects against AR-positive tumor cells in vitro. ... ...
